Ivan Kairatov is a leading expert in biopharmaceutical innovation with a distinguished career in research and development, specializing in the intersection of artificial intelligence and synthetic biology. As a key contributor to the development of high-throughput protein engineering frameworks, he
Managing severe, persistent respiratory conditions often feels like a relentless battle, with frequent treatments and the constant threat of debilitating flare-ups dictating the rhythm of daily life. For millions, conditions like severe asthma and chronic rhinosinusitis with nasal polyps represent
A groundbreaking Phase III clinical trial has revealed that the therapy Gazyva (obinutuzumab) demonstrates superior efficacy over the current standard-of-care treatment, tacrolimus, for adults grappling with primary membranous nephropathy. The MAJESTY trial’s success represents a significant
A single rogue protein, present in nearly every person diagnosed with amyotrophic lateral sclerosis, has long been the focus of intense scientific pursuit and a major roadblock to effective treatment. Netherlands-based biotechnology company VectorY Therapeutics has now initiated a landmark clinical
The emergence of cell-cultured protein has sparked intense debate at the intersection of agricultural tradition and technological innovation, nowhere more so than in states with deep roots in the livestock industry. In South Dakota, a legislative effort to completely prohibit the sale of lab-grown
Beijing Huaguan Biotechnology Co., Ltd., a pioneering force in synthetic biology and green chemical manufacturing, has officially closed its Series C financing round, securing hundreds of millions of RMB to accelerate its growth trajectory. This substantial capital infusion was driven by a
